看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。0 P+ g7 Q; \; \9 J8 u2 ~4 b" x
+ B6 Y1 O9 s- X& W, N
; v6 w* d+ Z V) H/ ^) R3 x; bCurrently available feasibility data for possible combination strategies.
" I. n* ?/ F5 T1 |+ f8 O" d$ p3 r————————————————————————————————( r* R, n( `& s& w( V0 ?
Combination Feasibility according to preliminary data
1 W! _/ w+ O. t' n* j$ G——————————————————————————————————
3 R; v2 O# W2 D( y- l* \1 BBevacizumab + sorafenib Yes, reduced dose
: [' D/ P! B2 m/ q1 T' S0 _0 A8 t+ o" fBevacizumab + sunitinib† No
9 `% R& V; u( ^* _- W- BBevacizumab + temsirolimus Yes ; N' ]9 `- b$ I G2 F: I6 X
Bevacizumab + everolimus Yes 5 a* |; ^1 Y- E# U
Sorafenib + sunitinib ?
; H5 {+ T c: V7 C h4 n* aSorafenib + temsirolimus Yes, reduced dose f3 n3 K; ]" N8 T0 j
Sorafenib + everolimus Yes, reduced dose
$ D2 Q1 ?0 m4 j( Q7 {Sunitinib + temsirolimus† No
k7 K. s: U; U: m5 S9 |Sunitinib + everolimus ?
+ w& _5 S! Z3 |Temsirolimus + everolimus ?
, R( t8 ?- I! R8 b) U' T$ ]" R5 n————————————————————4 c; E- r6 x/ z/ B4 z3 o1 x
†Led to US FDA warning.
# `2 \8 m6 Y% `. l, ^- l0 F?: As yet unattempted combination.6 T1 \: M* {- ?5 ]
|
显身卡
! r z4 U9 h1 I8 N
